RxDoctor Payments DataLook up a doctor →

Anjanette Tan, MD

Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1154326627

Payments from drug & device makers

$2,510,955in general payments, 2019–2025

Across 1,759 payments — averaging $1427.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.5M
  • AbbVie$334K
  • Novo Nordisk$201K
  • Novo Nordisk AS$196K
  • Sanofi US Services Inc.$100K
  • Biogen$68K
  • plus $153K from 54 others
$16,582in research payments, 2019–2025

Across 18 payments — averaging $921.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$15K
  • Corcept Therapeutics$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly114$1,458,601
AbbVie73$334,496
Novo Nordisk336$200,651
Novo Nordisk AS325$195,766
Sanofi US Services Inc.17$100,173
Biogen9$68,013
Esperion Therapeutics, Inc.67$47,201
Amgen(2 entities)100$32,751
GSK1$15,921
Corcept Therapeutics27$12,641
Boehringer Ingelheim Pharma GmbH & Co.kg3$11,685
Boehringer Ingelheim34$10,502
Fresenius Kabi USA, LLC6$4,641
Tandem Diabetes Care, Inc.18$3,277
Takeda Pharmaceuticals U.S.A., Inc.2$1,855
Abbott80$1,670
AstraZeneca(2 entities)74$1,444
Lilly USA, LLC74$1,357
Boehringer Ingelheim International GmbH11$887
Dexcom, Inc.45$755
IBSA Pharma Inc.7$694
Sanofi-aventis U.S. LLC39$665
Amarin Pharma, Inc.33$486
Mannkind Corporation20$448
Xeris Pharmaceuticals, Inc.22$394
Nevro Corp.12$277
Bayer18$257
Radius Health, Inc.11$246
Antares Pharma, Inc.12$234
Pfizer13$196
Merck14$192
Madrigal Pharmaceuticals7$182
Medtronic(2 entities)12$174
Alvogen Inc8$143
Neurocrine Biosciences, Inc.4$142
Ultragenyx Pharmaceutical Inc.7$114
Sequel Med Tech, LLC6$109
Ascendis Pharma Endocrinology Inc4$106
Insulet Corporation4$103
Amneal Pharmaceuticals LLC6$86
Recordati_rare_diseases_inc.4$81
Chiesi USA, Inc.3$80
Novartis3$79
Endo Pharmaceuticals Inc.4$73
Globus Medical3$68
Cequr Corporation3$67
Shire North American Group Inc4$60
Ascensia Diabetes Care US Inc.3$57
BETA Bionics, Inc.4$57
Verity Pharmaceuticals Inc.3$56
Vivus LLC4$55
Intuity Medical Inc3$52
Endo USA, Inc.2$48
Kyowa Kirin, Inc.2$42
Currax Pharmaceuticals LLC4$42
Clarus Therapeutics Inc.3$36
Blueprint Medicines Corporation2$36
Companion Medical, Inc.7$35
Soleno Therapeutics, Inc.1$35
Astellas Pharma US Inc2$34

How this compares

$2,510,955 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$324,412
Medicare patients
975
Services billed
3,902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Fort Worth

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →